Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Are European patents obstacles to Swedish cancer research?

Författare

Redaktör

  • Susanne Lundin
  • Lynn Åkesson

Summary, in English

Professor Håkan Olsson, Lund has addressed the problems caused by patenting in the field of biotechnology. His article was triggered by patent protection acquired by the American company Myriad Genetics. According to HO, Myriad requires that analyses of blood to trace the occurrence of these genes should be carried out in the company’s American laboratories, at a significant cost. Profit is infringing on the freedom of academic research and HO therefore asks:

• Is it reasonable to patent “inventions” in gene technology?

• Can patent protection be allowed to impede urgent, serious and non-commercial research?

• Can patent protection be circumvented by coercive measures?

• Should patentees be able to monopolize analytical work in medical care?

In this article I examine the system from a legal perspective. Are there solutions to the problems encountered by a researching physician, or must the rules be changed?

Publiceringsår

2002

Språk

Engelska

Sidor

52-71

Publikation/Tidskrift/Serie

Gene technology and economy

Dokumenttyp

Del av eller Kapitel i bok

Förlag

Nordic Academic Press

Ämne

  • Law

Nyckelord

  • civilrätt: immaterialrätt
  • private law: intellectual property law
  • biotechnology
  • patenting
  • research exemption.

Status

Published

ISBN/ISSN/Övrigt

  • ISBN: 9189116259